The Zolgensma® (onasemnogene abeparvovec) global Managed Access Program (gMAP) was created in 2020, the first of its kind for a one-time gene therapy, as a pathway while we worked to broaden global access to Zolgensma. The program was available and provided our gene therapy free of charge to eligible patients in countries where it was possible to make Zolgensma available, where it had not yet received approval, or where no access pathway existed.
During this time, nearly 300 children with spinal muscular atrophy (SMA) from 40 different countries were treated free of charge.1 These efforts were part of a broader initiative to address urgent medical needs while working towards sustainable, long-term access solutions in collaboration with local governments and payors.